Home › Compare › AATGF vs ABBV
AATGF yields 4444.44% · ABBV yields 3.06%● Live data
📍 AATGF pulled ahead of the other in Year 1
Combined, AATGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AATGF + ABBV for your $10,000?
ATI Airtest Technologies Inc. manufactures and sells air testing equipment and related services in Canada and the United States. It offers WiFi and EnOcean transmitters; carbon dioxide (CO2) transmitters for control of ventilation in buildings; parking garage ventilation products comprising stand alone gas transmitters, combined sensor/controllers, and custom configured control systems for on/off and variable modulation of fan systems; indoor wall mount dew point transmitters, indoor humidity and temperature transmitters, outside air dew point for economizer control, humidity and dew point probes, and surface condensation switches. The company also provides industrial air velocity, HVAC airflow monitoring, and low airflow/laminar airflow monitoring products; handheld and portable devices; CO2 modules, air velocity probes, humidity elements, humidity and temperature measurement modules and probes, and humidity calibration; sensors/transmitters and ventilation controllers for measuring gases; industrial low dew point; industrial humidity and temp measurement; moisture in oil transmitters and portable moisture in oil measurement; and materials and tools to perform calibrations on various sensors. ATI Airtest Technologies Inc. was incorporated in 1996 and is headquartered in Delta, Canada.
Full AATGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.